Saturday , November 17 2018
Breaking News
Home / BUSINESS / Lupin receives tentative approval from USFDA for generic Lurasidone Hydrochloride Tablets
Lupin receives tentative approval from USFDA for generic Lurasidone Hydrochloride Tablets

Lupin receives tentative approval from USFDA for generic Lurasidone Hydrochloride Tablets

Lupin has received tentative approval for its Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Sunovion Pharmaceuticals Inc.’s (Sunovion) Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.

Lupin’s Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg is the generic version of Sunovion’s Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg had annual sales of around $3116 million in the US (IQVIA MAT June 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Leave a Reply

Your email address will not be published. Required fields are marked *

*